Mesoblast Limited reported a significant revenue increase in the first quarter of fiscal year 2025, reaching US$20.6 million compared to US$12.9 million in the previous quarter. This growth was primarily driven by a 66% increase in Ryoncil gross sales, totaling US$21.9 million, and a 69% increase in net sales to US$19.1 million after adjustments. Ryoncil is the first MSC product approved by the FDA for children under 12 with SR-aGvHD, making it a key player in the market.

(Note: The news article includes a disclaimer at the end)

Read more at Nasdaq: Mesoblast Q1 Revenue From Cell Therapy Products Surges